UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regualting the PI3K/AKT signaling pathway

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Breast Cancer Chemosensitivity: Springer; 2007. p. 1–22.
   Google Scholar
• Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.
   PubMed Web of Science ®Google Scholar
• Sutter SA, Slinker A, Balumuka DD, et al. Surgical management of breast cancer in Africa: a continent-wide review of intervention practices, barriers to care, and adjuvant therapy. J Glob Oncol. 2017;3(2):162–168.
   PubMed Web of Science ®Google Scholar
• Luo P, Zhang C, Liao F, et al. Transcriptional positive cofactor 4 promotes breast cancer proliferation and metastasis through c-Myc mediated Warburg effect. Cell Commun Signal. 2019;17(1):36.
   PubMedGoogle Scholar
• Pavlides S, Vera I, Gandara R, et al. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal. 2012;16(11):1264–1284.
   PubMed Web of Science ®Google Scholar
• Zhou M-j, Chen F-z, Chen H-c. Ubiquitination involved enzymes and cancer. Med Oncol. 2014;31(8):93.
   PubMed Web of Science ®Google Scholar
• Rickman Kimberly A, Lach Francis P, Abhyankar A, et al. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of fanconi anemia. Cell Rep. 2015;12(1):35–41.
   PubMed Web of Science ®Google Scholar
• Luo C, Yao Y, Yu Z, et al. UBE2T knockdown inhibits gastric cancer progression. Oncotarget. 2017;8(20):32639–32654.
   PubMedGoogle Scholar
• Liu L-p, Yang M, Peng Q-z, et al. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun. 2017;493(1):20–27.
   PubMed Web of Science ®Google Scholar
• Wen M, Kwon Y, Wang Y, et al. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget. 2015;6(28):25226–25239.
   PubMedGoogle Scholar
• Gong YQ, Peng D, Ning XH, et al. UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncol Lett. 2016;12(6):4485–4492.
   PubMed Web of Science ®Google Scholar
• Perez-Peña J, Corrales-Sánchez V, Amir E, et al. Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Sci Rep. 2017;7(1):17530.
   PubMed Web of Science ®Google Scholar
• Ueki T, Park J-H, Nishidate T, et al. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 2009;69(22):8752–8760.
   PubMed Web of Science ®Google Scholar
• Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015;356(2 Pt A):156–164.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Loh K, Yap Y-S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12(4):342–354.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Voelker H-U, Kapp M, et al. Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol. 2010;136(2):219–225.
   PubMed Web of Science ®Google Scholar
• Avanzato D, Pupo E, Ducano N, et al. High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis. Cancer Res. 2018;78(13):3432–3444.
   PubMed Web of Science ®Google Scholar
• Jia L, Huang S, Yin X, et al. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sci. 2018;208:123–130.
   PubMed Web of Science ®Google Scholar
• Hao P, Kang B, Li Y, et al. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma. Mol Med Rep. 2019;20(2):1212–1220.
   PubMed Web of Science ®Google Scholar
• Wang Y, Leng H, Chen H, et al. Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K/Akt signaling pathway. Oncol Res. 2016;24(5):361–369.
   PubMed Web of Science ®Google Scholar
• Hu W, Xiao L, Cao C, et al. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway. Oncotarget. 2016;7(12):15161–15172.
   PubMedGoogle Scholar
• Kim W, Kim KS, Park RW. Nomogram of Naive Bayesian model for recurrence prediction of breast cancer. Healthc Inform Res. 2016;22(2):89–94.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang Y, Yang Z, et al. High expression of UBE2T predicts poor prognosis and survival in multiple myeloma. Cancer Gene Ther. 2019;26(11-12):347–355.
   PubMed Web of Science ®Google Scholar
• Huang P, Guo Y, Zhao Z, et al. UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. Aging (Albany NY). 2020;12(11):10275–10289.
   PubMedGoogle Scholar
• Liu J, Liu X. UBE2T silencing inhibited non-small cell lung cancer cell proliferation and invasion by suppressing the wnt/β-catenin signaling pathway. Int J Clin Exp Pathol. 2017;10(9):9482–9488.
   PubMed Web of Science ®Google Scholar
• Shen L, Zhao K, Li H, et al. Downregulation of UBE2T can enhance the radiosensitivity of osteosarcoma in vitro and in vivo. Epigenomics. 2019;11(11):1283–1305.
   PubMed Web of Science ®Google Scholar
• Yin H, Wang X, Zhang X, et al. UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation. Cancer Lett. 2020;494:121–131.
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–899.
   PubMed Web of Science ®Google Scholar
• Lim S-O, Li C-W, Xia W, et al. EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape. Cancer Res. 2016;76(5):1284–1296.
   PubMed Web of Science ®Google Scholar
• LoPiccolo J, Granville CA, Gills JJ, et al. Targeting Akt in cancer therapy. Anticancer Drugs. 2007;18(8):861–874.
   PubMed Web of Science ®Google Scholar
• Elstrom R, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–3899.
   PubMed Web of Science ®Google Scholar
• Yang SX, Polley EC, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016;45:87–96.
   PubMed Web of Science ®Google Scholar
• Saini KS, Loi S, De Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013;39(8):935–946.
   PubMed Web of Science ®Google Scholar